GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kaleido Biosciences Inc (OTCPK:KLDO) » Definitions » Revenue per Share

Kaleido Biosciences (Kaleido Biosciences) Revenue per Share : $0.03 (TTM As of Dec. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Kaleido Biosciences Revenue per Share?

Kaleido Biosciences's revenue per share for the three months ended in Dec. 2021 was $0.01. Kaleido Biosciences's revenue per share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Kaleido Biosciences's Revenue per Share or its related term are showing as below:

KLDO's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Kaleido Biosciences Revenue per Share Historical Data

The historical data trend for Kaleido Biosciences's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaleido Biosciences Revenue per Share Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Revenue per Share
Get a 7-Day Free Trial - - - 0.03 0.03

Kaleido Biosciences Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 - 0.01

Competitive Comparison of Kaleido Biosciences's Revenue per Share

For the Biotechnology subindustry, Kaleido Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaleido Biosciences's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's PS Ratio falls into.



Kaleido Biosciences Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Kaleido Biosciences's Revenue Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Revenue Per Share (A: Dec. 2021 )=Revenue (A: Dec. 2021 )/Shares Outstanding (Diluted Average) (A: Dec. 2021 )
=1.104/41.860
=0.03

Kaleido Biosciences's Revenue Per Share for the quarter that ended in Dec. 2021 is calculated as

Revenue Per Share (Q: Dec. 2021 )=Revenue (Q: Dec. 2021 )/Shares Outstanding (Diluted Average) (Q: Dec. 2021 )
=0.492/42.600
=0.01

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaleido Biosciences  (OTCPK:KLDO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Kaleido Biosciences Revenue per Share Related Terms

Thank you for viewing the detailed overview of Kaleido Biosciences's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaleido Biosciences (Kaleido Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.
Executives
Alison S Long officer: Chief Medical Officer KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Van Hylckama Vlieg Johan officer: Chief Scientific Officer C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Daniel L Menichella director, officer: Chief Executive Officer 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709
Kyriazi Theo Melas director 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8
Nutritional Health Ltp Fund General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Anne Prener director C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139
William E. Duke officer: CHIEF FINANCIAL OFFICER C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Richard William Scalzo officer: Principal Accounting Officer 25 ALBERTA LANE, HOLLISTON MA 01746
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Jerald Korn officer: General Counsel 128 GORDON RD, NEWTON MA 02468
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Michael W Bonney director, officer: Executive Chair 65 HAYDEN AVE, LEXINGTON MA 02421
Flagship Venturelabs V Manager Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142

Kaleido Biosciences (Kaleido Biosciences) Headlines